| Lupin’s focus in the region is on introducing world-class value-added niche products in various therapy areas. Its current basket of offerings comprises products from Anti-TB, Anti-Infectives, Anti-Asthma and Cardiovascular segments. Over the last three-years, Lupin has built a presence in key markets of these regions such as, Australia, UAE, Yemen, Kenya, Kuwait, Lebanon, Peru, Vietnam, Philippines.
The division’s most significant achievement of 2007 was the acquisition of Kyowa Pharmaceutical Industry Co. Ltd., in Japan which successfully positioned Lupin amongst the top ten generic companies in the world’s second largest pharma market.
Today, Lupin is the 3rd Indian company to have established a presence across the highly lucrative Gulf Cooperative Council markets comprising UAE and Saudi Arabia.
| 
